IL303117A - Preparations containing flumazenil and naltrexone and methods of using them - Google Patents

Preparations containing flumazenil and naltrexone and methods of using them

Info

Publication number
IL303117A
IL303117A IL303117A IL30311723A IL303117A IL 303117 A IL303117 A IL 303117A IL 303117 A IL303117 A IL 303117A IL 30311723 A IL30311723 A IL 30311723A IL 303117 A IL303117 A IL 303117A
Authority
IL
Israel
Prior art keywords
naltrexone
flumazenil
micrograms
administered
combination
Prior art date
Application number
IL303117A
Other languages
English (en)
Hebrew (he)
Original Assignee
Trexapharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904390A external-priority patent/AU2020904390A0/en
Application filed by Trexapharm Pty Ltd filed Critical Trexapharm Pty Ltd
Publication of IL303117A publication Critical patent/IL303117A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL303117A 2020-11-27 2021-11-26 Preparations containing flumazenil and naltrexone and methods of using them IL303117A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020904390A AU2020904390A0 (en) 2020-11-27 Compositions and methods
PCT/AU2021/051413 WO2022109677A1 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof

Publications (1)

Publication Number Publication Date
IL303117A true IL303117A (en) 2023-07-01

Family

ID=81753640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303117A IL303117A (en) 2020-11-27 2021-11-26 Preparations containing flumazenil and naltrexone and methods of using them

Country Status (9)

Country Link
US (4) US12521401B2 (enExample)
EP (1) EP4251168A4 (enExample)
JP (1) JP2024501919A (enExample)
KR (1) KR20230110793A9 (enExample)
CN (2) CN121695144A (enExample)
AU (2) AU2021388076B2 (enExample)
CA (1) CA3201498A1 (enExample)
IL (1) IL303117A (enExample)
WO (1) WO2022109677A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106574A1 (en) * 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety
USD1127473S1 (en) * 2023-12-28 2026-05-26 Ceragem Co., Ltd. Easy chair
JP1807091S (ja) * 2023-12-28 2025-08-26 安楽椅子
JP1807096S (ja) * 2023-12-28 2025-08-26 安楽椅子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
ES2289935B1 (es) 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
WO2010094074A1 (en) * 2009-02-20 2010-08-26 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20150111916A9 (en) * 2010-04-29 2015-04-23 Annette Channa Toledano Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
CA2899455C (en) * 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014186824A1 (en) * 2013-05-20 2014-11-27 Palmaya Pty Ltd Treatment of neurological and other disorders
EP3057596A4 (en) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Also Published As

Publication number Publication date
US12521401B2 (en) 2026-01-13
EP4251168A4 (en) 2024-11-06
WO2022109677A1 (en) 2022-06-02
CN121695144A (zh) 2026-03-20
AU2021388076B2 (en) 2025-08-14
US20240000796A1 (en) 2024-01-04
CN116648246A (zh) 2023-08-25
JP2024501919A (ja) 2024-01-17
US20260102405A1 (en) 2026-04-16
KR20230110793A (ko) 2023-07-25
KR20230110793A9 (ko) 2024-11-13
CA3201498A1 (en) 2022-06-02
US20260166054A1 (en) 2026-06-18
AU2021388076A1 (en) 2023-06-15
US20260166053A1 (en) 2026-06-18
AU2021388076A9 (en) 2024-08-08
EP4251168A1 (en) 2023-10-04
AU2025267401A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
AU2021388076B2 (en) Compositions comprising flumazenil and naltrexone and methods for use thereof
IL297912A (en) Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
CN101801406B (zh) 用于治疗淀粉样蛋白相关疾病的组织激肽释放酶
JP2023514559A (ja) 頭痛障害の幻覚剤処置
IL257276A (en) Methods for treating Knox-Gestaut syndrome using penforamine
IL283069B1 (en) Methods of administering corticosteroids
TW201729807A (zh) 用於治療癲癇的方法
IL262102A (en) Methods for treating eye conditions
JP2025513844A (ja) アルギナーゼ１欠損症の処置
Golub et al. Potential consequences of high-dose infusion of ketamine for refractory status epilepticus: case reports and systematic literature review
Besekar et al. Fabry disease and its management: a literature analysis
JP2024524679A (ja) アルツハイマー病の処置方法
IL273988B1 (en) Cannabidiol and chitosan compounds, and methods of using them
IL301409A (en) Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)
JP2005530751A (ja) 末端成長ホルモン（ｇｈ）断片を使用する鬱病の制御方法
JP6702883B2 (ja) 向神経活性ペプチドの安定な組成物
Lee et al. Oxytocin reduces methylphenidate-induced dorsal striatal dopamine release in male rhesus macaques
KR20240004706A (ko) 신경내분비 종양을 치료하기 위한 조성물 및 방법
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
Fritz Efficacy and Safety of Angiopoietin-like 3 Inhibitors in Decreasing Low-density Lipoprotein Cholesterol
Unzurrunzaga et al. Moxifloxacin-induced seizures in an epileptic patient
EA053081B1 (ru) Композиции и способы лечения нейроэндокринных опухолей
IL320087A (en) Methods for treating paediatric neurological disorders
IL301596A (en) Pharmacy composition
IL324041A (en) Methods of treating hepatic-only metastatic uveal melanoma